A Trial of CRD-4730 in HFrEF

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 525 participants.

Also called NCT07750873

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 525 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07750873
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07750873. Randomized; triple masking; primary purpose treatment. Start 2026-07-15 (actual); primary completion 2028-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Trial of CRD-4730 in HFrEF
Acronym
CALIBRATE-HF
Intervention (Drug)
CRD-4730
Intervention (Drug)
Placebo
Lead sponsor
Cardurion Pharmaceuticals, Inc. (class: industry)

Record details

Record id
cardio:ct-nct07750873
Content hash
af90b7b9eb3e65e8d156c26be3344af0f6816ed88254ad84f85dab636e0d4f98